SELLAS Life Sciences Group (NASDAQ:SLS) Trading 12.4% Higher – Should You Buy?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s share price was up 12.4% during trading on Monday . The stock traded as high as $11.15 and last traded at $11.2520. 4,462,403 shares were traded during trading, a decline of 47% from the average session volume of 8,411,522 shares. The stock had previously closed at $10.01.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Monday, July 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Friday, July 17th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, SELLAS Life Sciences Group has an average rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Stock Down 0.4%

The company’s fifty day moving average price is $10.75 and its two-hundred day moving average price is $6.98. The company has a market cap of $2.31 billion, a price-to-earnings ratio of -51.20 and a beta of 2.48.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01.

Institutional Trading of SELLAS Life Sciences Group

A number of hedge funds and other institutional investors have recently made changes to their positions in SLS. Geode Capital Management LLC raised its holdings in shares of SELLAS Life Sciences Group by 168.2% in the second quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company’s stock valued at $4,819,000 after buying an additional 1,379,988 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in SELLAS Life Sciences Group during the 2nd quarter worth about $136,000. Rhumbline Advisers acquired a new stake in SELLAS Life Sciences Group in the 2nd quarter valued at about $297,000. XTX Topco Ltd acquired a new stake in SELLAS Life Sciences Group in the 2nd quarter valued at about $168,000. Finally, New York State Common Retirement Fund bought a new position in shares of SELLAS Life Sciences Group in the second quarter worth about $108,000. 17.38% of the stock is currently owned by institutional investors and hedge funds.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.